MiMedx Group Forecasts Q1 Loss of 3 Cents Per Share, Revenue Plunge of 26%
summarizeSummary
Analysts expect MiMedx Group to report a first-quarter loss of 3 cents per share, alongside a significant 26.3% decrease in revenue to $65.02 million. This forecast aligns with the company's previous 10-K filing, which warned of substantial Medicare reimbursement cuts for skin substitutes impacting 2026 sales, and follows a recent 8-K detailing a cost reduction plan. The anticipated shift to a loss and material revenue decline quantifies the negative impact of these industry changes, reinforcing concerns about the company's near-term financial performance. Traders will be closely watching the actual Q1 earnings release on April 29 for confirmation or deviation from these analyst expectations, particularly as the stock trades near its 52-week low.
At the time of this announcement, MDXG was trading at $3.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $496.2M. The 52-week trading range was $3.19 to $7.99. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.